Ubrogepant

Summary

Ubrogepant (CHEMBL2364638) is an approved small molecule (ATC N02CD04); indicated across 1 condition including migraine disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02CD04
• Indications: 1 condition
• Clinical trials: 16
• Chemistry: 549.5 Da · C29H26F3N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2364638
Name	Ubrogepant
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	68748835
ATC	N02CD04
Molecular formula	C29H26F3N5O3
Molecular weight	549.5
InChIKey	DDOOFTLHJSMHLN-ZQHRPCGSSA-N

SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6

IUPAC name: (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6’-5,7-dihydrocyclopenta[b]pyridine]-3’-carboxamide

Also known as: MK-1602, Ubrelvy, Ubrogepant, Ubrogepant anhydrous, UBROGEPANT

Patent coverage: 184 distinct patent families (428 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 353 (82%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CGRP receptor	Antagonist	10.8

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, Calcitonin gene-related peptide type 1 receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
RAMP1	10.17	Ki	0.07	nM	CHEMBL_ACT_16888314
RAMP1	10.17	Ki	0.07	nM	CHEMBL_ACT_20657859
CALCRL	10.17	Ki	0.07	nM	CHEMBL_ACT_27425639
CALCRL	10.17	Ki	0.07	nM	CHEMBL_ACT_27562394

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	7
PHASE1	4
PHASE2	2
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05264129	PHASE4	COMPLETED	Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05125302	PHASE3	RECRUITING	Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05127954	PHASE3	ENROLLING_BY_INVITATION	Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
NCT06417775	PHASE3	RECRUITING	Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT02828020	PHASE3	COMPLETED	Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02867709	PHASE3	COMPLETED	Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02873221	PHASE3	COMPLETED	An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
NCT04492020	PHASE3	COMPLETED	Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
NCT01613248	PHASE2	COMPLETED	A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
NCT01657370	PHASE2	COMPLETED	A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
NCT04179474	PHASE1	COMPLETED	Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
NCT04818515	PHASE1	COMPLETED	Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
NCT05892757	PHASE1	COMPLETED	Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
NCT06578585	PHASE1	COMPLETED	A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
NCT06212661	Not specified	ENROLLING_BY_INVITATION	Migraine Medication Effects on Urinary Symptoms
NCT05654298	Not specified	COMPLETED	Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).